➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
McKesson
Moodys
Mallinckrodt
Baxter

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 7,794,976

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,794,976
Title:Methods and materials for expression of a recombinant protein
Abstract: Recombinant expression vectors are provided comprising a 3\'UTR of a light chain and an Epstein-Barr virus origin of replication. Also provided are host cells comprising such vectors and methods of producing recombinant protein with such vectors. Additional methods of producing a recombinant protein involve contacting cells with a first and second vector, each of which encode a different polypeptide chain, and wherein the second vector is present in an amount which is about 1.5 to 2.5 times as much as that of the first vector. Cells also can be transfected with a recombinant transient expression vector encoding a protein and are cultured in a medium in a membrane-enhanced culturing vessel to produce recombinant protein.
Inventor(s): Handa; Masahisa (Berkeley, CA), Horwitz; Arnold H. (San Leandro, CA), Cotter; Robyn (Oakland, CA), Batista; Eddie (San Francisco, CA)
Assignee: XOMA Technology Ltd. (Berkeley, CA)
Application Number:11/831,691
Patent Claims:see list of patent claims

Details for Patent 7,794,976

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial XOMA Technology Ltd. (Berkeley, CA) 2024-12-03 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial XOMA Technology Ltd. (Berkeley, CA) 2024-12-03 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial XOMA Technology Ltd. (Berkeley, CA) 2024-12-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
Medtronic
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.